Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Biosimilar CT-P13 on par with infliximab in Crohn’s Disease

06 Feb 2019

CT-P13 is as effective as its reference product (RP) infliximab for infliximab-naïve patients with Crohn’s disease (CD), suggests a recent study. Safety outcomes are also comparable between the two drugs.

The composite endpoint of death, CD-related surgery, all-cause hospitalization and reimbursement of another biologic therapy present in a total of 1,147 patients in the RP group and 952 in the CT-P13 group, as well as 838 and 719 hospitalizations, respectively.

Multivariable analysis revealed that CT-P13 was on a par with RP (HR, 0.92; 95 percent CI, 0.85–0.99). There were no between-group differences observed in safety outcomes: serious infections (HR, 0.82; 0.61–1.11), tuberculosis (HR, 1.10; 0.36–3.34), and solid or haematologic cancer (HR, 0.66; 0.33–1.32).

This comparative equivalence cohort study included 5,050 infliximab-naïve CD patients aged >15 years, who had started treatment with RP (n=2,551) or CT-P13 (n=2,400) and had no other indications for infliximab. Equivalence was defined as a 95 percent CI of the HR of CT-P14 vs RP in a multivariable marginal Cox model situated within prespecified margins (0.80–1.25).

The study was limited by incomplete clinical data from the Système National des Données de Santé, a French nationwide health administrative database (1 March 2015 to 30 June 2017).

“CT-P13 is a biosimilar of the RP infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of CD on that basis, without specific studies examining its effects in CD,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.